Thousands could be saved by making this small change to heart failure treatment - Giving medication up to a year earlier ...

Heart failure with reduced ejection fraction (HFrEF) represents a significant global health burden, affecting over 64 million individuals and resulting in substantial morbidity and mortality, ...

Discontinuing Beta-blocker therapy after an uncomplicated myocardial infarction (MI) was found to cause a persistent rise in ...

The findings hint at why the ABYSS trial failed to show it was safe to stop beta-blockers after an MI in stable patients.

The findings were eye-opening. Women who were on beta-blockers had a 4.6% greater chance of being hospitalized with heart failure after an acute coronary syndrome compared to men in the same ...

Heart failure represents one of the most significant global health challenges, affecting millions worldwide and requiring subsequent hospitalization for many patients due to complications.

Adapted from McMurray JJV. Major beta blocker mortality trials in chronic heart failure: a critical review. Heart. 1999;82(suppl 4):IV14 IV22. Altered adrenergic receptor sensitivity due to ...

Optimized treatment can reduce the mortality risk for chronic heart failure (HF ... angiotensin receptor/neprilysin inhibitors (ARNI), beta-blockers, mineralocorticoid receptor antagonists ...

We examine mortality trends of heart failure (HF) and acute myocarditis (AM) before and during the pandemic and identify the most affected demographic subgroups. We queried the Centers for Disease ...

They play a role in the development of acute and chronic vascular inflammation which is proposed as an underlying mechanism in the development of HFpEF (149). In the SATELLITE (121) (Safety and ...

The Get With the Guidelines-Heart Failure program was developed in 2005 with the goal ... with a higher overall risk profile were less likely to receive treatment with beta blockers and ...